Zacks: Analysts Anticipate Nuvectra Corp (NVTR) to Post -$0.65 EPS

Analysts predict that Nuvectra Corp (NASDAQ:NVTR) will announce earnings per share (EPS) of ($0.65) for the current quarter, Zacks reports. Three analysts have made estimates for Nuvectra’s earnings. The lowest EPS estimate is ($0.68) and the highest is ($0.62). Nuvectra reported earnings of ($0.84) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.6%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 1st.

According to Zacks, analysts expect that Nuvectra will report full-year earnings of ($2.77) per share for the current fiscal year, with EPS estimates ranging from ($2.80) to ($2.74). For the next year, analysts forecast that the company will post earnings of ($2.47) per share, with EPS estimates ranging from ($2.55) to ($2.39). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Nuvectra.

Nuvectra (NASDAQ:NVTR) last announced its earnings results on Thursday, February 28th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.15. Nuvectra had a negative net margin of 91.74% and a negative return on equity of 60.14%. The company had revenue of $14.53 million for the quarter, compared to analyst estimates of $15.58 million.

A number of equities analysts have recently issued reports on NVTR shares. BidaskClub upgraded shares of Nuvectra from a “hold” rating to a “buy” rating in a research report on Saturday, December 1st. Zacks Investment Research raised shares of Nuvectra from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Tuesday, January 1st. ValuEngine downgraded shares of Nuvectra from a “buy” rating to a “hold” rating in a research note on Saturday, February 2nd. Finally, Raymond James dropped their price target on shares of Nuvectra from $23.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $21.40.

Several institutional investors and hedge funds have recently modified their holdings of the company. American International Group Inc. increased its holdings in Nuvectra by 23.5% in the 4th quarter. American International Group Inc. now owns 11,394 shares of the company’s stock valued at $186,000 after buying an additional 2,166 shares during the period. PNC Financial Services Group Inc. boosted its position in Nuvectra by 231.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,318 shares of the company’s stock worth $54,000 after buying an additional 2,318 shares during the period. Teachers Advisors LLC boosted its position in Nuvectra by 13.4% during the 3rd quarter. Teachers Advisors LLC now owns 30,417 shares of the company’s stock worth $669,000 after buying an additional 3,600 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Nuvectra by 356.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,108 shares of the company’s stock worth $83,000 after buying an additional 3,989 shares during the period. Finally, MetLife Investment Advisors LLC raised its holdings in Nuvectra by 57.1% during the 3rd quarter. MetLife Investment Advisors LLC now owns 11,360 shares of the company’s stock worth $250,000 after purchasing an additional 4,128 shares during the last quarter. 81.64% of the stock is currently owned by institutional investors.

Shares of NVTR stock traded up $0.76 during trading hours on Monday, reaching $12.40. 6,010 shares of the company were exchanged, compared to its average volume of 214,990. Nuvectra has a fifty-two week low of $11.26 and a fifty-two week high of $25.17. The firm has a market capitalization of $206.02 million, a price-to-earnings ratio of -3.89 and a beta of 0.01. The company has a current ratio of 5.81, a quick ratio of 5.48 and a debt-to-equity ratio of 0.47.

About Nuvectra

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Read More: Trading Strategy Methods and Types

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.